Company
Endologix
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
2
510(k), De Novo and PMA
Device trials
24
As lead sponsor, any status
Adverse event reports
313
Received Nov 1, 2025 to Nov 20, 2026
Recall records
26
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Endologix, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Endologix.
Latest FDA decisions
- DETOUR SystemBreakthroughPMA
P220021 · Decided Jun 7, 2023 · 239 days after receipt
Device type: Stent graft, bypass, superficial femoral artery (QWM) · Cardiology
- Alto Abdominal Stent Graft SystemPMA supplement
P120006-S031 · Decided Mar 13, 2020 · 366 days after receipt · Panel Track
Device type: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT (MIH) · Cardiology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through RandomizationPivotal-lookingRecruiting
NCT05064540 · 450 participants (planned) · Start Sep 20, 2021 · Primary completion Mar 2032
Device: Alto Abdominal Stent Graft System; FDA Approved EVAR AAA Graft Systems · For: AAA; AAA - Abdominal Aortic Aneurysm
Sites: Huntsville, Alabama; Tucson, Arizona; Fayetteville, Arkansas · 29 sites in all
- The PQ Bypass Pivotal IDE Intra-arterial Stent Graft StudyPivotal-lookingCompleted
NCT04130737 · 188 participants · Start Aug 13, 2018 · Primary completion Jan 6, 2023
Device: TORUS Stent Graft System · For: Peripheral Arterial Disease
Sites: Mesa, Arizona; Phoenix, Arizona; Yuma, Arizona · 32 sites in all
- Nellix Registry Study: EVAS-GlobalCompleted
NCT02996396 · 48 participants · Start Nov 2016 · Primary completion Apr 25, 2023
Device: Nellix Endovascular Aneurysm Sealing System (Nellix®-System) · For: Abdominal Aortic Aneurysm
Sites: Augsburg, Germany; Bonn, Germany; Cologne, Germany · 10 sites in all
21 more trials with a free account
Reports received
313
Received Nov 1, 2025 to Nov 20, 2026. Includes 1 of another or unstated type.
Malfunction reports
13
4.2% of reports
Injury reports
283
90% of reports
Death reports
16
5.1% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 2 | 41 | 1 | 0 |
| Jan 24 | 2 | 22 | 0 | 0 |
| Feb 24 | 1 | 26 | 2 | 0 |
| Mar 24 | 0 | 39 | 0 | 0 |
| Apr 24 | 0 | 22 | 3 | 0 |
| May 24 | 0 | 39 | 0 | 0 |
| Jun 24 | 2 | 27 | 1 | 0 |
| Jul 24 | 0 | 28 | 1 | 0 |
| Aug 24 | 2 | 26 | 0 | 0 |
| Sep 24 | 1 | 17 | 0 | 0 |
| Oct 24 | 0 | 17 | 1 | 0 |
| Nov 24 | 1 | 24 | 1 | 0 |
| Dec 24 | 0 | 28 | 1 | 0 |
| Jan 25 | 1 | 22 | 0 | 0 |
| Feb 25 | 0 | 18 | 1 | 0 |
| Mar 25 | 0 | 23 | 0 | 0 |
| Apr 25 | 1 | 30 | 0 | 0 |
| May 25 | 0 | 37 | 14 | 0 |
| Jun 25 | 2 | 19 | 3 | 0 |
| Jul 25 | 0 | 25 | 0 | 0 |
| Aug 25 | 1 | 31 | 1 | 0 |
| Sep 25 | 0 | 19 | 1 | 0 |
| Oct 25 | 1 | 22 | 0 | 0 |
| Nov 25 | 0 | 16 | 0 | 0 |
| Dec 25 | 1 | 26 | 1 | 0 |
| Jan 26 | 0 | 10 | 1 | 0 |
| Feb 26 | 2 | 16 | 2 | 0 |
| Mar 26 | 1 | 26 | 1 | 0 |
| Apr 26 | 4 | 24 | 1 | 0 |
| May 26 | 3 | 18 | 0 | 0 |
| Jun 26 | 0 | 27 | 4 | 0 |
| Jul 26 | 1 | 32 | 1 | 0 |
| Aug 26 | 0 | 18 | 2 | 1 |
| Sep 26 | 1 | 24 | 2 | 0 |
| Oct 26 | 0 | 46 | 1 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2263-2020 · Started May 6, 2020 · Posted by FDA Jun 11, 2020
Reason given: A material weakness adjacent to the polymer fill channel may become compromised during pressurization with liquid polymer. Polymer leaks may occur during implantation of abdominal stent graft system. Clinical events related to polymer leaks may be systemic and/or aneurysm related.
Cause as FDA categorized it: Process control · Device type: System, Endovascular Graft, Aortic Aneurysm Treatment (MIH)
Z-0006-2019 · Started Jul 31, 2018 · Posted by FDA Oct 3, 2018
Reason given: Endologix is notifying physicians of patient tailored surveillance recommendations as well as general warnings/precautions for interventions to or through an existing AFX device. This is a follow-up notification to the one that was sent out in December 2016. The updates are related to the observation of Type III...
Cause as FDA categorized it: Device Design · Device type: System, Endovascular Graft, Aortic Aneurysm Treatment (MIH)
Z-0007-2019 · Started Jul 31, 2018 · Posted by FDA Oct 3, 2018
Reason given: Endologix is notifying physicians of patient tailored surveillance recommendations as well as general warnings/precautions for interventions to or through an existing AFX device. This is a follow-up notification to the one that was sent out in December 2016. The updates are related to the observation of Type III...
Cause as FDA categorized it: Device Design · Device type: System, Endovascular Graft, Aortic Aneurysm Treatment (MIH)
23 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.